Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Shots: Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM) Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma In late 2022,…

BySaurabh ChaubeySeptember 30, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in October 2022

The EMA approved 2 Biologic Drugs in October 2022, leading to treatments for patients and advances in the healthcare industryIn October 2022, the major highlights drugs were Yescarta approval for diffuse large B-cell lymphoma and high-grade B-cell lymphoma, and Adtralza for atopic dermatitisPharmaShots has compiled a list of a total of 2 new…

BySenior EditorNovember 23, 2022

TOP 20

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…

ByPrince GiriAugust 23, 2019

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Insights+: EMA Marketing Authorization of New Drugs in October 2022

Top 20 Life Sciences Deals of 2018 Based on Total Deal Value

Contact US

OUR INFORMATION

FOLLOW US